PHILADELPHIA, March 27, 2019 /PRNewswire/ -- Lannett
Company, Inc. (NYSE: LCI) today announced that it received approval
from the U.S. Food and Drug Administration (FDA) of its Abbreviated
New Drug Application (ANDA) for Aspirin and Extended-Release
Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to
the reference listed drug, Aggrenox® Capsules, 25 mg/200
mg, of Boehringer Ingelheim Pharmaceuticals, Inc. Total U.S.
sales of Aspirin and Extended-Release Dipyridamole Capsules, 25
mg/200 mg, was approximately $174.6
million for the 12 months ended January 2019, according to IQVIA, although actual
generic market values are expected to be lower.
"The commercial opportunity for our Aspirin and Extended-Release
Dipyridamole Capsules product, which was developed internally, is
meaningful," said Tim Crew, chief
executive officer of Lannett. "The launch of this product is
expected in the near term and is part of an ongoing and concerted
effort to add new products to our offering. Since January of
last year, we have commenced marketing nearly 20 products and we
expect to maintain that launch pace moving forward. We
continue to make substantial investments in product development and
expand in-licensing opportunities to replenish our pipeline, which
is sizable relative to our portfolio, and add revenues and improve
profitability."
About Lannett Company, Inc.:
Lannett Company, founded
in 1942, develops, manufactures, packages, markets and distributes
generic pharmaceutical products for a wide range of medical
indications. For more information, visit the company's
website at www.lannett.com.
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Any such statement, including, but not limited
to, successfully commercializing Aspirin and Extended-Release
Dipyridamole Capsules, 25 mg/200 mg, and the planned launches of
other products, whether expressed or implied, is subject to market
and other conditions, and subject to risks and uncertainties which
can cause actual results to differ materially from those currently
anticipated due to a number of factors which include, but are not
limited to, the risk factors discussed in the Company's Form 10-K
and other documents filed with the SEC from time to time, including
the prospectus supplement related to the proposed offering to be
filed with the SEC. These forward-looking statements
represent the Company's judgment as of the date of this news
release. The Company disclaims any intent or obligation to
update these forward-looking statements.
Contact:
|
Robert
Jaffe
|
|
Robert Jaffe Co.,
LLC
|
|
(424)
288-4098
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lannett-receives-fda-approval-for-aspirin-and-extended-release-dipyridamole-capsules-25-mg200-mg-300819106.html
SOURCE Lannett Company, Inc.